Besides insurance coverage, US government TrumpRX would provide these drugs at only US$350 per month soon and that could drop to US$250 in 2 years to qualified patients. In addition, new DTC channels of Eli Lilly & Novo Nordisk for US$500 or slightly lower, already much lower than their list prices for insurance plans and that would ease further in the future to US$300 for low dosage. When the new obesity pills are approved & ready, the price could be even lower.
Although securing government funding may not be too easy especially in some states, but the other major US public insurance Medicaid could see most states providing coverage soon too due to lower prices and the importance of lower long-term medical cost GLP-1 drugs will save the government on these programs. After over two years of successful track records of these drugs to tackle weight issues and studies on how much health benefit would these patients enjoy that would slash their health cost for the next few decades for them and for their insurance programs. Coverage from Medicaid plans as well as private commercial insurance plans will increase substantially.










